65.72
+5.37%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About GeneDx Holdings
From its filings with the US Securities and Exchange Commission
GeneDx Holdings is based in Stamford, Connecticut and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker WGS. The SEC classifies its business as health services. In the fiscal year to 31 December 2025, it reported revenue of $427.5m and a net loss of $21.0m. At that date it held total assets of $523.7m and shareholders' equity of $308.2m.
The Company’s Class A common stock and public warrants are listed on the Nasdaq Global Select Market under the symbols “WGS” and “WGSWW,” respectively.
At GeneDx, our mission is to empower everyone to live their healthiest life through genomics. GeneDx combines clinical expertise, advanced technology, and the proprietary GeneDx Infinity™ dataset to power the ExomeDx™ and GenomeDx™ tests – ranked #1 by expert geneticists and granted FDA Breakthrough Device Designation – enabling clinicians to deliver precise, fast, and actionable diagnoses. GeneDx InfinityTM also fuels discovery for biopharma while supporting the network that we believe will drive the future of precision genetic medicine. We believe that what is best for patients must be embedded in every aspect of our work, and in support of these beliefs, we value equitability, simplicity, and transparency.
GeneDx was founded in 2000 by scientists from the National Institutes of Health whose mission was to make genetic testing accessible for patients with rare diseases. The company quickly became a leader in genomics, creating the foundation for how to provide genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. 25 years later, we have amassed one of the world’s largest rare disease datasets, GeneDx InfinityTM, and remain a leader in genomics.
Quoted from its 10-K, filed 23 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 4 Sept 2020
- Employees
- 1,300
- Website
- sema4.com ↗
- Head office
- 333 LUDLOW STREET, STAMFORD, CT, 06902
- Incorporated in
- DE
- Classification
- Services-Health Services
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Jason RyanChairman of the Board, since 2021$859,950
- Ms. Katherine StuelandChief Executive Officer, Director, since 2022$4.4m
- Mr. Kevin FeeleyChief Financial Officer$1.3m
- Dr. Bryan DechairoChief Operating Officer
- Dr. Thomas FuchsDirector
- Mr. Eli CasdinIndependent Director$390,980
- Dr. Emily LeproustIndependent Director$405,980
- Mr. Keith MeisterIndependent Director$398,480
- Mr. Richard PfennigerIndependent Director$388,480
- Mr. Joshua RuchIndependent Director$398,480
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 21
- Environment
- 4
- Social
- 20
- Governance
- 38
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- GeneDx focuses on pediatric and rare disease diagnostics using whole exome and genome sequencing.
- Legacy Sema4 offers reproductive and women's health diagnostic testing and screening products.
- The company employs 1,100 full-time employees in the Health Care sector.
Weaknesses
- GeneDx Holdings Corp. went public on 4 September 2020 with an IPO.
- The company's segments include GeneDx and Legacy Sema4, which may require integration efforts.
- The firm's focus on genetic diagnostics may limit market diversification.
Opportunities
- GeneDx's personalized health insights can improve drug discovery processes.
- The Health Care sector continues to grow with increasing demand for genetic testing.
- Legacy Sema4's somatic oncology products can expand into new markets.
Threats
- The Health Care industry faces regulatory challenges in genetic testing.
- Competition in the genetic diagnostics market is intensifying.
- The company's reliance on specific diagnostic segments could pose risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.